Comparative Pharmacology
Head-to-head clinical analysis: HECTOROL versus ROCALTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HECTOROL versus ROCALTROL.
HECTOROL vs ROCALTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
Calcitriol, the active form of vitamin D, binds to vitamin D receptors in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone mineralization.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
Oral, 0.25 mcg once daily; may increase to 0.5 mcg once daily based on response. Typical adult dose is 0.25-0.5 mcg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Terminal elimination half-life is approximately 25–35 hours after oral administration. Clinical context: Once-weekly or thrice-weekly dosing achieves steady state in 1–2 weeks.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Primarily biliary/fecal; approximately 50% of dose recovered in feces within 24 hours. Renal excretion accounts for <5% of unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog